16.1 The following hypothalamic regulatory hormone is not a peptide:
A. Growth hormone release inhibitory hormone
B. Prolactin release inhibitory hormone
C. Gonadotropin releasing hormone
D. Corticotropin releasing hormone
16.2 Which hormone acts through a cytoplasmic receptor:
A. Calcitriol
B. Prolactin
C. Vasopressin
D. None of the above
16.3 Actions of growth hormone include the following except:
A. Increased protein synthesis
B. Increased fat utilization
C. Increased carbohydrate utilization
D. Glucose intolerance
16.4 Several actions of growth hormone are exerted through
the elaboration of:
A. Cyclic AMP
B. Cyclic GMP
C. Somatostatin
D. Insulin like growth factor-1
16.5 Octreotide is a long acting synthetic analogue of:
A. Prolactin
B. Growth hormone
C. Somatostatin
D. Gonadotropin releasing hormone
16.6 Somatostatin inhibits the release of:
A. Growth hormone
B. Insulin
C. Thyrotropin
D. All of the above
16.7 Indications of somatostatin include:
A. Macroprolactinoma
B. Zollinger Ellison syndrome
C. Bleeding esophageal varices
D. Steatorrhoea
16.8 Drugs that suppress growth hormone release in acromegaly include the following except:
A. Bromocriptine
B. Somatostatin
C. Octreotide
D. Nafarelin
16.9 For therapeutic use, growth hormone is obtained from:
A. Recombinant DNA technique
B. Human cadaver pituitaries
C. Porcine pituitaries
D. Chemical synthesis
16.10 Hyperprolactinemia can cause the following except:
A. Amenorrhoea
B. Gynaecomastia
C. Multiple ovulation
D. Depressed fertility
16.11 Bromocriptine causes the following:
A. Prolactin release
B. Vomiting
C. Uterine contraction
D. Impotence
16.12 The most prominent action of bromocriptine is:
A. Dopamine D2 agonism
B. Dopamine D2 antagonism
C. Dopamine D1 antagonism
D. α adrenergic antagonism
16.13 Gynaecomastia can be treated with:
A. Chlorpromazine
B. Cimetidine
C. Bromocriptine
D. Metoclopramide
16.14 Menotropins is a preparation of:
A. FSH + LH obtained from urine of menstruating women
B. LH obtained from urine of pregnant women
C. FSH + LH obtained from urine of menopausal women
D. LH obtained from serum of pregnant mare
16.15 The hypothalamic gonadotropin releasing hormone
(GnRH) is:
A. A single peptide
B. A mixture of two distinct peptides FSH-RH and LH-RH
C. A mixture of several peptides
D. Dopamine
16.16 Gonadotropins are indicated in the following conditions except:
A. Hypogonadotrophic hypogonadism in males
B. Cryptorchism in a boy less than 7 years old
C. Amenorrhoea and infertility in women
D. Polycystic ovaries
16.17 Superactive GnRH agonists cause:
A. Initial as well as sustained release of gonadotropins
B. Initial inhibition followed by stimulation of gonadotropin release after 1-2 weeks
C. Initial stimulation followed by inhibition of gonadotropin release after 1-2 weeks
D. Initial as well as sustained inhibition of gonadotropin release
16.18 Thyrotropin exerts the following actions on the thyroid
gland except:
A. Increases vascularity
B. Inhibits proteolysis of thyroglobulin
C. Induces hyperplasia and hypertrophy
D. Promotes iodide trapping
16.19 Serum TSH levels are high in most cases of:
A. Myxoedema
B. Grave’s disease
C. Carcinoma thyroid
D. Toxic nodular goiter
16.20 Adrenocorticotropic hormone is primarily used for:
A. Treatment of Addison’s disease
B. Treatment of congenital adrenal hyperplasia
C. Treatment of autoimmune diseases
D. Diagnosis of pituitary-adrenal axis disorders
16.1 B 16.2 A 16.3 C 16.4 D 16.5 C 16.6 D 16.7 C 16.8 D 16.9 A 16.10 C
16.11 B 16.12 A 16.13 C 16.14 C 16.15 A 16.16 D 16.17 C 16.18 B 16.19 A 16.20 D